EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer

Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer. NICE technology appraisal guidance 258 (2012).

Lung cancer for adults. NICE quality standard 17 (2012).

Erlotinib monotherapy for the maintenance treatment of non-small-cell lung cancer. NICE technology appraisal guidance 227 (2011).

Lung cancer: the diagnosis and treatment of lung cancer. NICE clinical guideline 121 (2011).

Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer. NICE technology appraisal guidance 192 (2010).

Pemetrexed for the maintenance treatment of non-small-cell lung cancer. NICE technology appraisal guidance 190 (2010).

Pemetrexed for the first-line treatment of non-small-cell lung cancer. NICE technology appraisal guidance 181(2009).

Erlotinib for the treatment of non-small-cell lung cancer. NICE technology appraisal guidance 162 (2008).

Endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal masses. NICE interventional procedure guidance 254 (2008).

Pemetrexed for the treatment of non-small-cell lung cancer. NICE technology appraisal guidance 124 (2007).

Crizotinib for the treatment of previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene. NICE technology appraisal. Publication expected September 2013.

Afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer. NICE technology appraisal. Publication expected June 2014.

Erlotinib and gefitinib for the treatment of non-small-cell lung cancer following prior chemotherapy (Review of TA162 and TA175). NICE technology appraisal. Publication expected June 2014.

Pemetrexed for maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer. NICE technology appraisal. Publication date to be confirmed.